| References |
1. Jinnouchi H, Nozaki K, Watase H, Omiya H, Sakai S, Samukawa Y. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus. Adv Ther. 2016 Feb 5. [Epub ahead of print] PubMed PMID: 26846284. 2. Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin Ther. 2016 Jan 1;38(1):66-88.e20. doi: 10.1016/j.clinthera.2015.10.025. Epub 2015 Dec 22. PubMed PMID: 26718606. 3. Nishimura R, Omiya H, Sugio K, Ubukata M, Sakai S, Samukawa Y. The sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control assessed by continuous glucose monitoring even on a low-carbohydrate diet. Diabetes Obes Metab. 2015 Dec 6. doi: 10.1111/dom.12611. [Epub ahead of print] PubMed PMID: 26639943. 4. Qiang S, Nakatsu Y, Seno Y, Fujishiro M, Sakoda H, Kushiyama A, Mori K, Matsunaga Y, Yamamotoya T, Kamata H, Asano T. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015 Nov 19;7:104. doi: 10.1186/s13098-015-0102-8. eCollection 2015. PubMed PMID: 26594248; PubMed Central PMCID: PMC4653899. |
